About one in ten of the mutations behind inherited disease works the same crude way. A single letter in a gene flips to spell "stop" too early, and the cell obediently halts, churning out a stub of protein that does nothing. These nonsense mutations show up in Duchenne muscular dystrophy, in cystic fibrosis, in dozens of rare metabolic disorders that most people never hear of. Fixing them has always meant building a bespoke tool for each broken gene, one costly program at a time.
A team led by Sarah E. Pierce and David R. Liu at the Broad Institute has now demonstrated a way around that, and the trick is to leave the broken gene alone entirely. Their approach, reported in Nature, edits the cell's translation machinery instead of the mutation itself. It is one fix that, in principle, could work no matter which gene carries the premature stop.
Rewriting the cell's own adaptor
The idea rests on a molecule most people last thought about in a biology class. Transfer RNAs, or tRNAs, are the adaptors that read the genetic code three letters at a time and drop the matching amino acid into a growing protein. A "suppressor" tRNA is one engineered to read a stop signal as an ordinary amino acid, forcing the ribosome to keep going past the premature halt. Researchers have chased this idea for years, but the usual delivery methods demand either lifelong dosing or so much suppressor tRNA that the cell starts to suffer.
Pierce and colleagues took a different route. They used prime editing, the precise gene-writing method Liu's lab helped pioneer, to permanently rewrite one of the cell's own spare tRNA genes into a suppressor. No extra copies flooding the cell. No repeated injections. One edit at a single spot in the genome, and the cell makes its own corrected adaptor from then on.
Getting there took brute-force screening. The researchers worked through thousands of variants spanning all 418 human tRNA genes, hunting for the ones that could be nudged into strong suppressor activity without wrecking their normal job. They call the resulting strategy PERT, for prime editing-mediated readthrough of premature termination codons.
From three cell models to a rescued mouse
In human cells carrying disease mutations, it worked across a genuinely mixed bag of disorders. Cells modeling Batten disease, Tay-Sachs disease, and cystic fibrosis all showed the ribosome reading through the premature stop and rebuilding the missing protein. That range matters, because the whole selling point is generality. The same editing agent does not care which gene is broken; it cares only about the stop codon in the way.
The most striking result came in a living animal. In mice modeling Hurler syndrome, a severe metabolic disease caused by a missing enzyme, a single prime editor that converted an endogenous mouse tRNA into a suppressor extensively rescued the disease pathology. That is the difference between a clever cell-culture demonstration and something that hints at therapy.
Any readthrough approach carries an obvious worry. If you teach the machinery to ignore a stop signal, does it start ignoring the legitimate stop codons that end every normal protein? The authors checked, and reported no detected readthrough of natural stop codons, along with no significant changes across the cells' broader RNA and protein profiles. The edited suppressor tRNA seems to act narrowly, on the premature stops it was built for.
What still stands between here and the clinic
Restraint is still in order. These are cell models and mouse models, not patients, and the leap from a rescued mouse to a safe, durable human treatment is long and littered with programs that stumbled. Prime editing itself still faces the delivery problem that shadows all in-body gene editing: getting the machinery into the right tissues at the right dose. Hurler syndrome affects many organs, and how thoroughly the edit reaches each of them in a human body is an open question. The paper is a proof of principle, and it reads like one.
Still, the framing is what makes it interesting. Most gene-editing therapies are one-mutation, one-drug propositions, which is part of why they cost so much and reach so few people. A single "composition of matter" that could address a whole class of nonsense mutations flips that economics. Whether PERT survives the long road to the clinic is unknown. But it points at a version of genetic medicine that does not require reinventing the treatment for every patient.
Comments